157 related articles for article (PubMed ID: 26073694)
1. The Quality of Curative-intent Radiotherapy for Non-small Cell Lung Cancer in the UK.
McAleese J; Baluch S; Drinkwater K
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):498-504. PubMed ID: 26073694
[TBL] [Abstract][Full Text] [Related]
2. The Elderly are Less Likely to Receive Recommended Radical Radiotherapy for Non-small Cell Lung Cancer.
McAleese J; Baluch S; Drinkwater K; Bassett P; Hanna GG
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):593-600. PubMed ID: 28735769
[TBL] [Abstract][Full Text] [Related]
3. The management of lung cancer: a UK survey of oncologists.
Prewett SL; Aslam S; Williams MV; Gilligan D
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):402-9. PubMed ID: 22516859
[TBL] [Abstract][Full Text] [Related]
4. Service Improvements and Workload Increases: Royal College of Radiologists (RCR) Re-Audit of Curative Intent Radiotherapy for Non-Small Cell Lung Cancer (NSCLC).
McAleese J; Drinkwater K;
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):e128-e136. PubMed ID: 38616447
[TBL] [Abstract][Full Text] [Related]
5. Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea.
Song S; Chang JH; Kim HJ; Kim YS; Kim JH; Ahn YC; Kim JS; Song SY; Moon SH; Cho MJ; Youn SM
Cancer Res Treat; 2017 Jul; 49(3):688-694. PubMed ID: 27809459
[TBL] [Abstract][Full Text] [Related]
6. The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance.
Beasley M; Brown S; McNair H; Faivre-Finn C; Franks K; Murray L; van Herk M; Henry A
Br J Radiol; 2019 Jun; 92(1098):20180988. PubMed ID: 30924682
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
8. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
9. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
De Ruysscher D; Wanders R; van Haren E; Hochstenbag M; Geraedts W; Pitz C; Simons J; Boersma L; Verschueren T; Minken A; Bentzen SM; Lambin P
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):132-8. PubMed ID: 18037581
[TBL] [Abstract][Full Text] [Related]
10. Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.
Sanganalmath P; Lester JE; Bradshaw AG; Das T; Esler C; Roy AEF; Toy E; Lester JF; Button M; Wilson P; Comins C; Atherton P; Pickles R; Foweraker K; Walker GA; Keni M; Hatton MQ
Clin Oncol (R Coll Radiol); 2018 Mar; 30(3):144-150. PubMed ID: 29336865
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
12. [Impact of PET/CT on precise radiotherapy planning for non-small cell lung cancer].
Gong HY; Yu JM; Fu Z; Li BS; Li JB; Liu TH
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):54-7. PubMed ID: 16737623
[TBL] [Abstract][Full Text] [Related]
13. [Standards, Options and Recommendations for the management of stage I or II primary bronchial cancers treated exclusively with radiotherapy].
Touboul E; Lagrange JL; Theobald S; Astoul P; Baldeyrou P; Bardet E; Bazelly B; Bréchot J; Breton JL; Douillard JY; Grivaux M; Jacoulet P; Khalil A; Le Chevalier T; Lemarie E; Martinet Y; Massard G; Milleron B; Moro-Sibilot D; Paesmans M; Pujol JL; Quoix AE; Ranfaing E; Rivière A; Sancho-Garnier H; Souquet PJ; Spaeth D; Stoebner-Delbarre A; Thiberville L; Vaylet F; Vergnon JM; Westeel V; Depierre A
Cancer Radiother; 2001 Aug; 5(4):452-63. PubMed ID: 11521393
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
[TBL] [Abstract][Full Text] [Related]
16. Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort.
Evison M; Barrett E; Cheng A; Mulla A; Walls G; Johnston D; McAleese J; Moore K; Hicks J; Blyth K; Denholm M; Magee L; Gilligan D; Silverman S; Hiley C; Qureshi M; Clinch H; Hatton M; Philipps L; Brown S; O'Brien M; McDonald F; Faivre-Finn C
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):145-154. PubMed ID: 32978027
[TBL] [Abstract][Full Text] [Related]
17. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
[TBL] [Abstract][Full Text] [Related]
18. Impact of 3D conformal radiotherapy on lung function of patients with lung cancer: a prospective study.
Enache I; Noel G; Jeung MY; Meyer N; Oswald-Mammosser M; Pistea C; Jung GM; Mennecier B; Quoix E; Charloux A
Respiration; 2013; 86(2):100-8. PubMed ID: 23154264
[TBL] [Abstract][Full Text] [Related]
19. Investigating the potential impact of four-dimensional computed tomography (4DCT) on toxicity, outcomes and dose escalation for radical lung cancer radiotherapy.
Cole AJ; O'Hare JM; McMahon SJ; McGarry CK; Butterworth KT; McAleese J; Jain S; Hounsell AR; Prise KM; Hanna GG; O'Sullivan JM
Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):142-50. PubMed ID: 24332210
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy patterns of care for stage I and II non-small cell lung cancer in Sydney, Australia.
Nguyen AD; Wong W; Beydoun N; Mohan S; Shafiq J; Vinod SK
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):131-141. PubMed ID: 30281917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
